Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma

Journal of the Canadian Urological Association

Volumn 1, Issue 2 SUPPL, 2007, Pages

  Kapoor, Anil K ^a   Hotte, Sébastien J ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84860331162     PISSN: 19116470     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Motzer RJ, Vogelzang NJ. Chemotherapy for renal cell carcinoma. In: Raghaven D, editor. Principles and practice of genitourinary oncology. Philadelphia: Lippincott-Raven; 1997. p. 885-96.
2. Yagoda A. Chemotherapy of renal cell carcinoma. Semin Urol 1989;7:199-206.
3. Harris DT. Hormonal and chemotherapy of renal cell carcinoma. Semin Oncol 1983; 10:422-30.
4. de Riese W, Goldenberg K, Allhoff E, et al. Metastatic renal cell carcinoma (RCC): spon-taneous regression, long-term survival and late recurrence. Int Urol Nephrol 1991;23: 13-25.
5. Coppin C, Porzsolt F, Kumpf J, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; (3):CD001425.
6. Kurzrock R, Talpaz M, Gutterman JU. Interferons: basic principles and preclinical studies. In: DeVita VT, Hellman S, Rosenberg SA, editors. Biologic therapy of cancer. Philadelphia: J.B. Lippincott; 1991. p. 247-74.
7. Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am1993; 20:283-95.
8. Bukowski RM, Novick AC. Clinical practice guidelines: renal cell carcinoma. Cleve Clin J Med 1997;64(Supp 1):SI1-48.
9. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombi-nant interferon alpha-2A, or both in metastatic renal cell carcinoma. N Engl J Med1998; 338:1272-8.
10. Steineck G, Strander H, Carbin BE, et al. Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial. Acta Oncol 1990;29:155-62.
11. Porzsolt F, Messerer D, Hautmann R, et al. Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medrox-yprogesterone acetate. A randomized multicenter trial. J Cancer Res Clin Oncol 1988; 114:95-100.
12. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999;17:2859-67.
13. Fossa SD, Martinelli G, Otto U. Recombinant interferon alpha-2A with or without vin-blastine in metastatic renal cell carcinoma: results of a European multi-center phase III study. Ann Oncol 1992;3:301-5.
14. Kriegmair M, Oberneder R, Hofstetter A. Interferon alfa and vinblastine versus medrox-yprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology 1995;45:758-62.
15. Medical Research Council Renal Cancer Collaborators. Interferon alpha and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet1999; 353:14-7.
16. Yang JC, Rosenberg SA. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J Sci Am 1997; 3(Suppl 1):S79-84.
17. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metasta-tic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. JClin Oncol 1995;13:688-96.
18. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol2003;21:3127-32.
19. Gleave ME, Elhilali M, Fradet Y, et al. Interferon gamma-1b compared with placebo in metastatic renal cell carcinoma. N Engl J Med 1998;338:1265-71.
20. Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma -medical progress. N Engl J Med 1996;335:865-75.
21. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose inter-leukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133-41.
22. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-97.
23. Law TM, Motzer RJ, Mazumdar M, et al. Phase III randomized trial of interleukin-2 with or without lymphokine lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 1995;76:824-32.
24. Fisher RI, Rosenberg SA, Sznol M, et al. High dose aldesleukin in renal cell carcino-ma: long term survival update. Cancer J Sci Am 1997;3:S70-2.
25. Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: role of interleukin-2. Cancer 1997;80:1198-220.
26. Negrier S. Better survival with interleukin-2-based regimens? Possibly only in highly selected patients. J Clin Oncol 2004;22:1174-6.
27. Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus inter-leukin-2 administration in patients with metastatic cancer. Cancer1998;83:797-805.
28. Phan GQ, Morton KE, Liewehr DJ, et al. Quality of life in patients with metastatic renal cell cancer receiving different regimens of interleukin-2. [abstract]. Proc Am Soc Clin Oncol 2002;21:25a.
29. Gallagher DC, Bhatt RS, Parikh SM, et al. Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak. Clin Cancer Res 2007;13:2115-20.
30. Buter J, Sleifer DT, Vander Graaf WT, et al. A progress report on the outpatient treat-ment of patients with advanced renal cell carcinoma using subcutaneous recombi-nant interleukin-2. Semin Oncol 1993;20:16-21.
31. Hotte S, Waldron T, Canil C, et al. Interleukin-2 in the treatment of unresectable or metastatic renal cancer: a systematic review and practice guideline. CUAJ2007;1:27-38.
32. Yang JC, Topalian SL, Parkinson D. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an inter-im report. J Clin Oncol 1994;12:1572-6.
33. Yang JC, Rosenberg RA. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J Sci Am 1997; 3(Suppl 1):S79-84.
34. Atzpodien J, Kirchner H, Jonas U, et al. Interleukin-2 and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004;22:1188-94.
35. Atzpodien J, Kirchner H, Illiger HJ, et al. IL-2 in combination with IFN-a and 5-FU ver-sus tamoxifen in metastatic renal cell carcinoma: long term results of a controlled clinical trial. Br J Cancer 2001;85:1130-6.
36. Boccardo F, Rubagotti A, Canobbio L, et al. Interleukin-2, interferon-α and inter-leukin-2 plus interferon-a in renal cell carcinoma. A randomized phase II trial. Tumori 1998;84:534-9.
37. Henriksson R, Nilsson S, Colleen S, et al. Survival in renal cell carcinoma -a random-ized evaluation of tamoxifen vs. interleukin-2, alpha-interferon (leucocyte) and tamox-ifen. Br J Cancer 1998;77:1311-7.
38. Lummen G, Goepel M, Mollhoff S, et al. Phase II study of interferon-gamma versus interleukin-2 plus interferon-alpha2b in metastatic renal cell carcinoma. J Urol 1996; 155:455-8.
39. Atkins MB, Sparano J, Fisher RI, et al. Randomized phase II trial of high-dose inter-leukin-2 either alone or in combination with interferon alpha-2b in advanced renal cell carcinoma. J Clin Oncol 1993;11:661-70.
40. Quan WD Jr, Vinogradov M, Quan FM, et al. Continuous infusion interleukin-2 and famo-tidine in metastatic kidney cancer. Cancer Biother Radiopharm 2006;21:515-9.
41. Negrier S, Perol D, Ravaud A, et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial [abstract]. [Ann Meet Proc]. J Clin Oncol 2005;23(16S Suppl Pt 1):4511.
42. Hudes G, Carducci M, Tomczak P, et al. A phase 3, randomized 3-arm study of tem-sirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC) [abstract]. [Ann Meet Proc]. J Clin Oncol 2006;24(Suppl 18):LBA4.